- Home
- COYA vs RVPH Comparison
COYA vs RVPH Comparison
Compare COYA & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- RVPH
- Stock Information
- Founded
- COYA 2020
- RVPH 2006
- Country
- COYA United States
- RVPH United States
- Employees
- COYA N/A
- RVPH N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- RVPH Health Care
- Exchange
- COYA Nasdaq
- RVPH Nasdaq
- Market Cap
- COYA 93.9M
- RVPH 87.6M
- IPO Year
- COYA 2022
- RVPH N/A
- Fundamental
- Price
- COYA $5.38
- RVPH $1.77
- Analyst Decision
- COYA Strong Buy
- RVPH Strong Buy
- Analyst Count
- COYA 4
- RVPH 5
- Target Price
- COYA $16.25
- RVPH $12.00
- AVG Volume (30 Days)
- COYA 62.0K
- RVPH 3.3M
- Earning Date
- COYA 11-06-2024
- RVPH 11-14-2024
- Dividend Yield
- COYA N/A
- RVPH N/A
- EPS Growth
- COYA N/A
- RVPH N/A
- EPS
- COYA N/A
- RVPH N/A
- Revenue
- COYA $9,554,315.00
- RVPH N/A
- Revenue This Year
- COYA N/A
- RVPH N/A
- Revenue Next Year
- COYA $87.80
- RVPH N/A
- P/E Ratio
- COYA N/A
- RVPH N/A
- Revenue Growth
- COYA N/A
- RVPH N/A
- 52 Week Low
- COYA $4.75
- RVPH $0.60
- 52 Week High
- COYA $10.69
- RVPH $4.83
- Technical
- Relative Strength Index (RSI)
- COYA 38.98
- RVPH 49.95
- Support Level
- COYA $5.52
- RVPH $1.56
- Resistance Level
- COYA $6.14
- RVPH $1.86
- Average True Range (ATR)
- COYA 0.44
- RVPH 0.25
- MACD
- COYA -0.01
- RVPH -0.03
- Stochastic Oscillator
- COYA 5.13
- RVPH 34.43
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.